Henry Schein, Inc. (HSIC) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is modestly constructive — consensus is a manageable bar and the biggest swing factor is the pace of value-creation savings acceleration in Q2, which management explicitly flagged as the first meaningful step-up quarter.

Heading into the Q2 2026 print, the bar looks achievable: consensus non-GAAP EPS of ~$1.24 implies roughly 13% year-over-year growth versus the depressed Q2 2025 base ($1.10), and revenue consensus of ~$3.37B sits just modestly above the prior-year $3.24B. Management's posture on the May 5 call was constructive — dental momentum was explicitly confirmed through May, medical underlying growth (ex-flu diagnostics) was tracking mid-single digits into Q2, and the FX tailwind that boosted Q1 reported revenue is expected to diminish, creating a modest headwind to reported growth. Estimate revisions have been stable-to-slightly-positive since the Q1 beat, with the EPS consensus ticking up from ~$1.21 post-print to ~$1.24 currently, suggesting the Street has modestly raised the bar but not aggressively. The stock has rallied ~16% since the Q1 print (vs. XLV +12%), pricing in continued execution but not yet a blowout; at ~15x NTM P/E, valuation remains below historical averages, leaving room for multiple expansion if the value-creation ramp is visible. The key wildcard is the magnitude of G&A savings from the shared-service-center buildout — management guided for acceleration in Q2 and a more significant step-up in H2, and any quantification of the run-rate savings trajectory will be the most watched data point on the call.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable but not low bar — the ~13% EPS growth implied by the $1.24 estimate is achievable given the weak Q2 2025 comp, but the bigger swing factor is non-GAAP operating income, where the value-creation savings ramp is the key variable. Revenue consensus of $3.37B is essentially in line with the organic growth trajectory management described.

Table 1 — Current Quarter Snapshot (Q2 2026)

Sources: Visible Alpha Consensus and Actuals Data

Table 2 — Beat/Miss History (Last 8 Quarters)

Non-GAAP Diluted EPS

Total Revenue

Pattern: HSIC has beaten EPS consensus in 5 of the last 7 reported quarters, with the sole miss in Q2 2025 driven by the glove pricing headwind and targeted promotional activity that compressed margins. Revenue beats have been more consistent in recent quarters (Q1–Q4 2025) after a period of misses during the cyber-incident recovery phase (Q3–4 2024). The trend suggests the Street has learned to set a conservative bar, and management has regained execution credibility.

Source: Visible Alpha Consensus and Actuals Data

3. Guidance & Commentary Evolution

Key Takeaway: Guidance is unchanged since the May 5 Q1 2026 earnings call — no post-earnings events have revised the numbers. The tone, however, has shifted slightly negative on the margin with the July 30 COO/CSO leadership transition announcement, which introduces modest execution uncertainty heading into the H2 value-creation ramp.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been stable-to-modestly-higher since the Q1 2026 print, with EPS consensus ticking up ~$0.03 for Q2 and ~$0.01 for FY2026 — a sign the Street absorbed the Q1 beat constructively but is not aggressively front-running the value-creation ramp. The gap between consensus and guidance midpoint is narrow, leaving limited cushion if execution disappoints.

Estimates have been remarkably stable since the Q1 print, with essentially no revision in either direction for revenue or EPS — the Street is holding its position and waiting for Q2 data to confirm the value-creation ramp. The FY2026 EPS consensus of $5.35 sits ~1% above the guidance midpoint of $5.30, a narrow cushion that leaves little room for error if H2 savings delivery disappoints.

Source: Visible Alpha Consensus and Actuals Data

5. Stock Performance

Key Takeaway: HSIC has outperformed XLV (+16% vs. +12%) since the Q1 print, driven by a combination of multiple re-rating (EV/EBITDA expanded from ~10.5x to ~11.7x over 3 months) and modest estimate upgrades — suggesting the market is rewarding execution credibility and the value-creation narrative rather than just earnings revisions.

The chart below shows HSIC, XLV (Health Care Select Sector SPDR ETF), and SPY (S&P 500) indexed to 100 at the Q1 2026 earnings date (May 5, 2026). XLV is used as the sector benchmark given HSIC’s classification within the healthcare distribution sub-sector.

[Image not found: gs://lum-production-user-data/conversations/conv_01k1aqhqhkfhkbhkbhkbhkbhk/plotly_charts/hsic_stock_performance.json]

HSIC vs. XLV vs. S&P 500 — Indexed to 100 at May 5, 2026 (Q1 2026 Earnings Date)

Indexed Performance Since May 5, 2026 (Q1 2026 Earnings Date) — Selected Dates:

Note: Indexed values computed from raw close prices (HSIC base: $74.37, XLV base: $145.30, SPY base: $723.77 on May 5, 2026). XLV (Health Care Select Sector SPDR) is the appropriate sector benchmark for HSIC given its healthcare distribution classification. Material event marked: July 30, 2026 — COO/CSO leadership transition announcement.

Performance decomposition: Over the 3-month window, HSIC’s +17% gain was driven roughly equally by multiple expansion (EV/EBITDA from ~10.5x to ~11.7x, contributing ~+11%) and earnings estimate upgrades (~+1%), with the remainder attributable to sentiment re-rating as the value-creation narrative gained credibility. The stock pulled back ~2% from its mid-July high following the July 30 COO/CSO transition announcement but has since partially recovered. At 15.1x NTM P/E vs. a 3-year average closer to 17–18x, HSIC still trades at a discount to its own history, suggesting further re-rating potential if H2 execution is clean.

Source: Stock Price Data (Yahoo Finance); Stock Performance Decomposition (Implied)

6. Peer Commentary Read-Through

Screening Methodology Note: Only peer commentary made within the last 60 days (on or after June 4, 2026) that explicitly addresses conditions during the April–June 2026 quarter (HSIC’s current reporting period) or forward conditions relevant to HSIC’s Q2 2026 results is included. Prior-quarter earnings calls discussing Q1 2026 results (e.g., commentary from May 2026 calls about Q1 performance) are excluded unless they contain explicit forward guidance or commentary about Q2 2026 or beyond. Each entry includes an explicit relevance and limitations assessment.

Key Takeaway: Align Technology’s Q2 2026 earnings (July 29) provide the most directly relevant read-through: dental patient demand was stable-to-growing in Q2, DSO channels remained strong, and the capital equipment market continued to face ASP pressure from lower-priced entrants — all consistent with HSIC’s own Q1 narrative and supportive of a clean Q2 print on the dental side.

Align Technology (ALGN) — Q2 2026 Earnings Call, July 29, 2026

Relevance Score: High (Dental Equipment & Patient Demand)

• Dental patient demand stable-to-growing in Q2 2026: ALGN reported record Q2 clear aligner volumes of 692,000 cases, up 7.4% year-over-year, with growth “broad based across customer channels, patient segments, and geographies.” A record 89,200 doctors submitted cases globally, with doctor utilization up 3.8%. This is a direct positive read-through for HSIC’s dental merchandise and consumables volumes in Q2 2026, confirming that dental practices remained active and patient traffic was healthy through the quarter.
• North America described as “stable”: CEO Joe Hogan characterized North America as “stable — no better and no worse than what we have seen before,” with “continued strength in orthodontic and DSO channels helping to offset slower retail demand.” The DSO channel strength is directly relevant to HSIC, which has been explicitly targeting DSO wallet-share expansion as a growth driver. Stable North America dental demand supports HSIC’s Q2 dental merchandise consensus.
• Capital equipment ASP pressure persists: ALGN’s Systems & Services revenue fell 11% year-over-year in Q2 due to “persistent softness in the capital equipment market” and a “shift toward lower-priced scanners and flexible acquisition models (leasing and rental).” Despite this, scanner unit placements to new doctors reached a record level and grew double digits. This is a direct read-through for HSIC’s digital equipment segment, where management has already flagged intraoral scanner ASP pressure from new lower-priced entrants. The volume-up/revenue-flat dynamic ALGN described is consistent with HSIC’s Q1 2026 digital equipment commentary and suggests the same pattern likely continued in Q2.
• International markets (EMEA, APAC, LatAm) delivered double-digit volume growth: Positive read-through for HSIC’s international dental segment, which grew 13.4% in Q1 2026 and where management cited strength in Germany, UK, Canada, Australia, and New Zealand.
• Q3 2026 outlook: ALGN guided Q3 clear aligner volume up mid-single digits year-over-year, with scanner revenue down sequentially due to seasonality and continued mix shift to lower-priced products. This is a forward read-through for HSIC’s Q3 2026 dental equipment outlook.

Limitations: ALGN’s business is concentrated in clear aligners and intraoral scanners — a subset of HSIC’s much broader dental distribution portfolio. ALGN’s commentary does not speak to traditional dental consumables (gloves, materials, PPE), traditional equipment, or HSIC’s medical and specialty segments. The UK VAT ruling impact on ALGN pricing is specific to clear aligners and not relevant to HSIC.

Envista Holdings (NVST) — Investor Day Announcement, July 28, 2026

Relevance Score: Low-Moderate (Dental Market Sentiment)

• Investor Day scheduled for September 17, 2026: Envista announced an Investor Day on July 28, 2026, signaling management confidence in the dental market outlook and willingness to engage investors with a forward-looking strategic update. While no specific Q2 2026 commentary was available, the scheduling of an Investor Day is a mild positive sentiment signal for the broader dental market heading into HSIC’s Q2 print.

Limitations: No Q2 2026 earnings or operational commentary was available from Envista within the screening window. The Investor Day announcement alone provides limited read-through for HSIC’s specific Q2 results.

Dentsply Sirona (XRAY) — Q2 2026 Earnings Call Scheduled August 6, 2026

Relevance Score: Pending (Reports After HSIC)

• XRAY will report Q2 2026 results on August 6, 2026 — one day after HSIC. No Q2 2026 commentary is available within the screening window. XRAY is a meaningful read-through for dental equipment and consumables demand given its direct exposure to the same dental practice customer base. Investors should monitor XRAY’s August 6 call for confirmation of the dental market trends HSIC reports.

Limitations: No current-quarter commentary available; XRAY reports after HSIC.

Peers Screened But Excluded

7. Material News & Developments

Key Takeaway: The most important development since the Q1 print is the July 30 announcement that COO Michael Ettinger and CSO Mark Mlotek will transition to advisory roles effective October 30, 2026 — a meaningful leadership change that introduces execution risk precisely as the value-creation program enters its most critical H2 ramp phase.

• July 30, 2026 — COO & CSO to Transition to Advisory Roles (8-K): Henry Schein announced that EVP & COO Michael S. Ettinger and EVP & CSO Mark E. Mlotek will transition out of their current roles effective October 30, 2026, moving into senior advisory positions. Both are entitled to payments under the Executive Severance Plan. This is the most significant post-earnings development: Ettinger and Mlotek are long-tenured executives who have been central to the company’s operational and strategic execution. Their departure coincides with the critical H2 2026 period when value-creation G&A savings are expected to accelerate most significantly. Successors have not been named. Implication: Investors will likely ask management on the Q2 call about succession planning and whether the leadership transition affects the $125M value-creation run-rate target timeline.
• May 5, 2026 — Q1 2026 Earnings Beat; FY2026 Guidance Reaffirmed: HSIC reported Q1 2026 non-GAAP EPS of $1.32 (vs. consensus $1.21, +9.1% beat) and revenue of $3.368B (vs. consensus $3.341B). Full-year 2026 guidance was reaffirmed at $5.23–$5.37 non-GAAP EPS and +3% to +5% revenue growth. New CEO Fred Lowry’s first earnings call emphasized continuous improvement culture, operational agility, and AI-driven product development. Implication: Sets a higher bar for Q2 execution; the Street now expects the value-creation ramp to be visible in Q2 numbers.
• May 5, 2026 — SIN 360 Consolidation Completed; Remeasurement Gain of $11M (~$0.07/share): HSIC completed the acquisition of a controlling interest in S.I.N. 360 (U.S. distributor of SIN Brazil value implants) in Q1 2026, generating a one-time remeasurement gain. Further JV consolidation gains, if any, are not expected until H2 2026. Implication: No similar one-time gain expected in Q2; EPS comparison should be clean.
• May 4, 2026 — HSIC to Participate in Investor Conferences in May: Henry Schein announced participation in investor conferences in May 2026. No material guidance updates were disclosed at these events (guidance remained unchanged through the screening window). Implication: Neutral; no incremental data points emerged.
• Ongoing — E-Commerce Platform Rollout (henryschein.com): As of Q1 2026, over 80% of U.S. dental e-commerce sales were transacted on the new platform, with full U.S. rollout expected by end of August 2026. Canadian and U.S. laboratory customers already deployed. Implication: Completion of the U.S. rollout in Q2/early Q3 is a positive operational milestone that could support customer retention and cross-sell metrics.
• Ongoing — Tariff & Oil Price Mitigation: Management flagged on the Q1 call that further merchandise price increases were anticipated in Q2 as a consequence of higher oil prices, with mitigation measures in place (fuel surcharges, customer redirection to own brands/private label). Implication: Gross margin in Q2 will be watched closely for evidence that oil/tariff headwinds are being successfully offset.
• Align Technology (ALGN) Q2 2026 Results (July 29, 2026): ALGN reported record clear aligner volumes (+7.4% YoY) and stable North American dental demand, with DSO channel strength. Capital equipment ASP pressure from lower-priced scanner entrants continued. Implication: Positive read-through for HSIC dental consumables; confirms the digital equipment ASP headwind HSIC has flagged is an industry-wide dynamic.

8. Insider Transaction Activity

Key Takeaway: The only open-market insider transaction since the Q1 2026 earnings date is a $770K open-market purchase by Director Daniel William K on May 11, 2026 — a constructive signal from a board member buying shortly after the Q1 beat. No insider sales have been disclosed in the period. The absence of sales is notable given the stock’s ~16% rally since the print.

Source: Insider Transaction Data (SEC Form 4 Filings)

Note: Only open-market buys (code P) and sells (code S) plus 10b5-1 plan initiations are included. No open-market sales or 10b5-1 plan initiations were identified for HSIC in the May 5 – August 3, 2026 window. The COO and CSO leadership transition announced July 30 may result in future Form 4 filings related to severance plan equity provisions; these should be monitored.

9. Key Questions for Management

Key Takeaway: The Q2 call will be defined by three questions: (1) how much of the $125M value-creation run-rate is now visible in the P&L, (2) what is the succession plan for the COO and CSO roles, and (3) whether the dental market momentum management confirmed through May has held through June.

1. Value-Creation Savings Quantification: Management guided for G&A savings to “accelerate in Q2 and even more so in Q3 and Q4.” Can you quantify the Q2 G&A savings run-rate achieved? How does the shared-service-center buildout track against the $125M year-end target? What is the gross profit initiative contribution in Q2?
2. COO/CSO Succession Planning: With Michael Ettinger and Mark Mlotek transitioning to advisory roles effective October 30, who will assume their operational and strategic responsibilities? Does this change the timeline or confidence level for the H2 value-creation ramp?
3. Dental Market Momentum Through June: On the Q1 call, you confirmed dental momentum was continuing through May. Did that momentum hold through June? Were there any signs of softening in patient traffic or practice investment as the quarter progressed?
4. Medical Business Recovery: Q1 medical growth was 1.3% reported (mid-single digits ex-flu diagnostics). With the flu season headwind lapping, what is the underlying medical growth rate in Q2? Is the Home Solutions business continuing to grow above the segment average?
5. Digital Equipment ASP Dynamics: Align Technology confirmed continued intraoral scanner ASP pressure from lower-priced entrants in Q2, with unit volumes up but revenue flat-to-down. Is HSIC seeing the same dynamic in its digital equipment sales? At what point does ASP compression become a structural headwind vs. a temporary mix effect?
6. Oil/Tariff Mitigation Progress: You guided for further merchandise price increases in Q2 due to higher oil prices. Were you able to fully offset the freight and product cost headwinds within Q2 gross margins? Has the oil price environment changed your confidence in the full-year guidance assumptions?
7. FX Tailwind Diminishing: Q1 benefited from a ~3.1% FX tailwind to reported revenue and ~$0.03 EPS benefit. You indicated this would diminish as the year progresses. What is the expected FX impact on Q2 reported revenue and EPS?
8. Capital Allocation — Buyback Pace: You repurchased $125M of stock in Q1 at an average of $77.64/share. With the stock now ~$86, has the buyback pace changed? How much of the $655M remaining authorization do you expect to deploy in 2026?
9. Specialty Products Growth Acceleration: Q1 specialty LCI growth was 1.7%, below the segment’s total reported growth rate due to timing. Management expected improvement through the year. Did specialty LCI growth accelerate in Q2 as expected? What is driving the timing normalization?
10. 2027 Guidance Preview: With the $125M value-creation run-rate entering 2027 as a key variable, can you provide any early framing for 2027 earnings growth potential? Is double-digit EPS growth in 2027 still the base case?